齊默巴奧米特控股 ZBH 深 滬
已收盤 10-31 16:00:00 美东时间
100.56
+1.000
+1.00%
華盛通- 最 高101.865
- 今 開98.65
- 成交量 212.48万股
- 最 低 98.00
- 昨 收 99.56
- 總市值 199.11亿
- 52周最高 113.96
- 市盈率 靜 22.69
- 換手率 1.07%
- 52周最低 88.74
- 委 比 90.48%
- 總股本 1.98亿
- 歷史最高 172.24
- 量 比 1.93
- 振 幅 3.88%
- 歷史最低 31.94
- 每 手 1
- 風險率 6.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Grants Breakthrough Device Designation For Zimmer Biomet's First-To-World Iodine-Treated Total Hip Replacement System
Prioritized Regulatory Review Process in the U.S. Follows Japan PMDA Approval in SeptemberWARSAW, Ind., Oct. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology
10-28 19:37
Zimmer Biomet’s Refobacin Revision-3 Study: A Market Game Changer?
Zimmer Biomet Holdings (($ZBH)) announced an update on their ongoing clinical s...
10-28 02:25
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Maintains $101 Price Target
Canaccord Genuity analyst Caitlin Roberts maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and maintains $101 price target.
10-22 22:04
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Demystifying Zimmer Biomet Holdings: Insights From 7 Analyst Reviews
During the last three months, 7 analysts shared their evaluations of Zimmer Bio...
10-14 02:01
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Lowers Price Target to $104
Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:ZBH) with a In-Line and lowers the price target from $106 to $104.
10-08 02:03
Zimmer Biomet Completes Acquisition of Monogram Technologies
Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for ort...
10-07 21:00
Zimmer Biomet Secures PMDA Japan Approval For iTaperloc Complete And iG7 Hip Systems, Orthopedic Implants With Iodine Anti-Bacterial Technology
iTaperloc® Complete and iG7™ Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on the implant surface to help address the issue of Periprosthetic Joint
09-26 04:33
